Cargando…
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer
ARID1A, an epigenetic tumor suppressor, is the most common gene mutation in clear-cell ovarian cancers (CCOCs). CCOCs are often resistant to standard chemotherapy and lack effective therapies. We hypothesized that ARID1A loss would increase CCOC cell dependency on chromatin remodeling and DNA repair...
Autores principales: | Kinose, Yasuto, Xu, Haineng, Kim, Hyoung, Kumar, Sushil, Shan, Xiaoyin, George, Erin, Wang, Xiaolei, Medvedev, Sergey, Ferman, Benjamin, Gitto, Sarah B., Whicker, Margaret, D’Andrea, Kurt, Wubbenhorst, Bradley, Hallberg, Dorothy, O’Connor, Mark, Schwartz, Lauren E., Hwang, Wei-Ting, Nathanson, Katherine L, Mills, Gordon B., Velculescu, Victor E., Wang, Tian-Li, Brown, Eric J., Drapkin, Ronny, Simpkins, Fiona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571599/ https://www.ncbi.nlm.nih.gov/pubmed/37841875 http://dx.doi.org/10.21203/rs.3.rs-3314138/v1 |
Ejemplares similares
-
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
por: Xu, Haineng, et al.
Publicado: (2021) -
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020) -
Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
por: Rødland, Gro Elise, et al.
Publicado: (2021) -
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2020) -
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)